Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAYHIT1: Ianalumab plus first-line corticosteroids in primary immune thrombocytopenia
jRCT2061220095Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in immune thrombocytopenia (ITP) (3 arms), sponsored by Novartis. Primary endpoint: Rate of Stable Response off treatment at 12 months (SROT-12). Started Jun 2023; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2061220095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220095.